Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Donaueschingen – page 29

591 clinical trials in Donaueschingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Donaueschingen at a glance
591
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

591 trials in Donaueschingen

Open in trial search

Crohn's disease

Not recruiting

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Secukinumab and Prednisone for Patients with Polymyalgia Rheumatica Who Have Recently Relapsed

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Study on Allogeneic Stem Cell Transplantation for Children and Adolescents with Acute Lymphoblastic Leukemia Using Etoposide, Treosulfan, and Thiotepa

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Study on Symptom Changes in Adults with Chronic Rhinosinusitis with Nasal Polyps Using Tezepelumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:AstraZeneca AB

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Prometheus Biosciences Inc.

Faricimab for Choroidal Neovascularization Secondary to Pathologic Myopia in Patients with Pathologic Myopia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Faricimab
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Serplulimab
  • Sponsor:Shanghai Henlius Biotech Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Donaueschingen

What the registry says about research in the country

01 Pulmonary Research

Groundbreaking clinical trials focusing on pulmonary arterial hypertension (PAH) are exploring innovative treatment approaches. The research aims to evaluate new therapeutic interventions for patients dealing with this challenging cardiovascular condition.

  • Treatment Efficacy Assessment
  • Safety Profile Evaluation
  • Clinical Progression Monitoring

These studies are designed to track and assess clinical outcomes in PAH patients, with particular attention to preventing disease progression and improving patient well-being.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.